AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00074581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Study NCT00074581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Study NCT00074581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage depends on weight
Study NCT00074581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally once daily
Study NCT00074581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine
Description: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Study NCT01372722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Activa PC systems Medtronic
Description: 130Hz, 90us pulsewidth, 4V Amplitude
Study NCT01372722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS, Activa PC systems Medtronic
Description: 30Hz, 90us pulsewidth, 4V Amplitude
Study NCT01491295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
Study NCT01491295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine plus adefovir
Description: Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
Study NCT00351416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 20 mg orally one time
Study NCT00351416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 691751, dose 6
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 691751
Description: oral solution
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo solution
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 691751, dose 2
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 691751, dose 5
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: 1 tablet
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 691751, dose 3
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 69175, dose 4
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 691751, dose 7
Study NCT01843972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751
Description: oral solution BI 69175, dose 1
Study NCT02232126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SWIFT home intervention
Description: 1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
Study NCT00041054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00041054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00041054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exisulind
Study NCT05116150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
Study NCT05116150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape seed extract
Description: Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
Study NCT05116150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
Study NCT03500718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
Study NCT02036814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Health Education
Study NCT01328132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
Study NCT01328132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% albumin
Description: 100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
Study NCT03823742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
Study NCT03823742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
Study NCT01339143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galvus (vildagliptin)
Description: 50mg BID, PO, for 16 weeks
Study NCT01339143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 15mg, QD, PO, 16 weeks
Study NCT00694642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Selected CD 133+ cells
Description: Endothelial progenitor cell CD 133
Study NCT02268175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
Study NCT02268175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
Study NCT02268175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
Study NCT02268175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
Study NCT00553891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
Study NCT00553891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: One spray in each nostril once daily for 3 months.
Study NCT02132026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Study NCT02132026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronic Acid
Study NCT02132026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab Placebo
Description: subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
Study NCT02132026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronic Acid Placebo
Description: Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
Study NCT01143246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution.
Study NCT01143246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
Study NCT05116150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
Study NCT03410017 — intervention group
Intervention type: OTHER
Intervention: Functional Listening Index
Description: Functional Listening Index questionnaire to assess acquisition of listening skills.
Study NCT04031820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar cup
Description: Cemented unipolar acetabulum cup for primary THA
Study NCT04031820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual mobility cup
Description: Cemented dual mobility acetabulum cup for primary THA
Study NCT01148849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: margetuximab
Description: margetuximab
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil, adjusted dose
Description: 3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids, IV
Description: 10-15 mg/kg IV pre-operation on Day 0
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids, IV
Description: 10-15 mg/kg IV pre-operation on Day 0
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil, Standard dose
Description: 2 g/d PO BID during meals from Day 0 to Month 12
Study NCT00545402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids, PO
Description: 20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
Study NCT00916539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cast that immobilizes the thumb
Description: Cast that immobilizes the thumb
Study NCT00916539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast that does not immobilize the thumb
Description: Cast that does not immobilize the thumb
Study NCT02187679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Study NCT01714778 — intervention group
Intervention type: OTHER
Intervention: e-Cigarette
Study NCT01497496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Methylprednisolone (HDMP)
Description: 1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
Study NCT01497496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
Study NCT01905163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Debulking Surgery by laparoscopy
Study NCT03086265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: active nasal oxygen delivery system
Study NCT03086265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Plastic tube for supporting ventilation during surgery
Study NCT02073071 — intervention group
Intervention type: OTHER
Intervention: Preterm infant formula per standard of care
Description: Commercially available preterm infant formula
Study NCT01848886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic radial artery harvest
Description: Radial artery harvest is performed as an endoscopic procedure.
Study NCT01848886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open radial artery harvest
Description: Radial artery harvest is performed as an open procedure.
Study NCT01848886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mammarioradial graft (Y-graft)
Description: The radial artery is used as an composite graft positioned on the internal mammarian artery.
Study NCT01848886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aortoradial graft (Free RA)
Description: The radial artery is used as an free graft positioned on the aorta.
Study NCT04054089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]
Description: Biktarvy OD
Study NCT04054089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dolutegravir 50 mg / lamivudine 300 mg
Description: DTG +3TC (Dovato OD)
Study NCT01984164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: blinded
Study NCT01984164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Blinded
Study NCT04620850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
Study NCT01713751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suturing
Description: Skin is closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
Study NCT01713751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suturing
Description: Skin is closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\]
Study NCT02208297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Gel (BID)
Description: One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
Study NCT02208297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel (BID)
Description: One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
Study NCT03718065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
Study NCT03718065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.
Study NCT03031379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shortened fast
Description: fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
Study NCT05144568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Nutrition education will be given to improve PMS
Study NCT02810847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Bit plus
Description: The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
Study NCT02128451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperdine
Description: 15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
Study NCT02128451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
Study NCT01908972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 2mg/kg/day for 16weeks
Study NCT01908972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 2mg/kg/day for 16weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training - Fixed Schedule
Description: Supervised aerobic training for 40 minutes 3x/week for 20 weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training - Fixed Schedule
Description: Supervised resistance training for 20 minutes 3x/week for 20 weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking program
Description: Unsupervised walking program 1-3 days/week for 52 weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training - Flexible Schedule
Description: Supervised aerobic training done on the participant's own schedule for 32 weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training - Flexible Schedule
Description: Supervised resistance training done on the participant's own schedule for 32 weeks
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Successful Survivorship Health Education and Support Group
Description: Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
Study NCT02763228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexible support groups
Description: Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
Study NCT01877915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Study NCT01877915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
Study NCT01877915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care for heart failure and coronary artery disease
Description: Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Study NCT01877915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care for heart failure and coronary artery disease
Description: Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
Study NCT02866799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-PAP
Description: Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
Study NCT02866799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.
Study NCT02866799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive the usual clinical care based on current clinical practice guidelines.
Study NCT03779971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.